274 results on '"Stilgenbauer, Stephan"'
Search Results
2. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
3. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies
4. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
5. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study
6. Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL
7. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
8. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
9. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations
10. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia
11. The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
12. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia
13. Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia
14. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia
15. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
16. U-RT1 – A new model for Richter transformation
17. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
18. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
19. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia
20. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
21. FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL
22. CLL-246 Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 5-Year Results of the Randomized CLL14 Study
23. Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma
24. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
25. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies
26. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
27. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
28. Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
29. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy
30. Postibrutinib outcomes in patients with mantle cell lymphoma
31. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
32. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
33. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
34. CLL-465 Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)
35. Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)
36. Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
37. NOTCH1 Signaling Is Dysregulated in CLL By the Deubiquitinase USP28 That Is Recurrently Affected By Del(11q) and Can be Therapeutically Targeted
38. A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)
39. Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
40. Novel BTK Mutations Conferring Resistance to Non-Covalent BTK Inhibitors and Alternative Treatment Strategy
41. Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome
42. Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial
43. Preliminary Results of Voice (Virtual Opinions poll Independent Centered on CLL patients’ Experience): A Global Survey to Assess the Disease-Specific Knowledge and Perspectives of Real-World Patients with CLL
44. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
45. Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial
46. Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
47. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
48. Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells
49. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment
50. Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.